DIA Biosimilars 2013

Amarin

Longitude Capital closes second life sciences fund with $385M

Friday, October 12, 2012 12:13 PM

Longitude Capital has closed the Longitude Venture Partners II, a $385 million venture capital fund dedicated to investments in drug development and medical technology. 

More... »

Cenduit: Now with Patient Reminders

FDA approves Vascepa for severe hypertriglyceridemia

Friday, July 27, 2012 10:53 AM

The FDA has approved Vascepa (icosapent ethyl) capsules as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (TG ≥ 500mg/dL), according to Amarin, a Bedminster, N.J.-based biopharmaceutical company focused on cardiovascular health.

More... »

CRF Health – eCOA Forum

Amarin reveals positive results from ANCHOR trial for AMR 101

Monday, April 18, 2011 12:27 PM

Amarin, a clinical-stage biopharmaceutical company focusing on cardiovascular disease, reported positive, statistically significant results from its ANCHOR trial for the company's lead product candidate, AMR101.,  The trial was a multi-center, placebo-controlled, randomized, double-blind, 12-week pivotal study, that enrolled 702 patients.  The phase III trial met its primary and secondary efficacy endpoints for both the 4 gram and 2 gram daily doses.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs